Biogen Idec Inc (BIIB) 319.12 $BIIB
Regado's REGULATE-PCI Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:30PM CDT
The FDA has placed a clinical hold on patient enrollment and dosing in Regado Biosciences, Inc.'s (RGDO) ongoing phase III REGULATE-PCI study.
Myriad Genetics Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:10PM CDT
On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. (MYGN).
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 10:30AM CDT
Celgene's (CELG) Otezla failed to meet the primary endpoint in a late stage study.
Lexicon (LXRX) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 8:46AM CDT
Lexicon (LXRX) was a big mover last session, with shares rising nearly 8% on the day.
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM
at The Street - Thu Jul 10, 5:00AM CDT
Cramer says Williams is a bargain, Unum is a slow and steady grower and Alcoa is reinventing itself.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
China Biologic Products, Inc. (CBPO) Jumps: Stock Surges 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:11AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:33AM CDT
Ultragenyx Pharmaceutical has seen flat earnings estimate revisions for the current quarter along with a significant rise in its share price for the past day
'Fast Money' Recap: Waiting for the Dust to Settle
at The Street - Wed Jul 09, 4:00AM CDT
The trading panel discussed the market's fall and how to hedge your positions.
Sanofi's Basal Insulin Candidate Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 5:40PM CDT
Sanofi's (SNY) new drug application for its basal insulin candidate, Toujeo, has been accepted for review by the FDA.
Biogen Idec Falls 2.48% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 2.48% Loss
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Jumps after Pain Drug Performs Well in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 3:45PM CDT
BioDelivery announced positive top-line results from a pivotal phase III efficacy study evaluating their pain candidate, BEMA buprenorphine.
Alexion Pharma Looks To Life Beyond Its Blockbuster
at Investor's Business Daily - Tue Jul 08, 1:42PM CDT
Like a rock band's second album, a biotech's second drug can say a lot about its long-term prospects. Alexion Pharmaceuticals (ALXN) is about to face this test. The 22-year-old firm has become a big-cap and a perennial on the IBD 50 list of top-rated...
Bristol-Myers Gains Japanese Approval for HCV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 10:40AM CDT
Bristol-Myers' (BMY) HCV combo drug has been cleared in Japan.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
BioDelivery Sciences International (BDSI) Rises: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 8:04AM CDT
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Oncolytics Biotech Inc. (ONCY) in Focus: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 7:44AM CDT
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.
Regado's REGULATE-PCI Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:30PM CDT
The FDA has placed a clinical hold on patient enrollment and dosing in Regado Biosciences, Inc.'s (RGDO) ongoing phase III REGULATE-PCI study.
Myriad Genetics Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:10PM CDT
On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. (MYGN).
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 10:30AM CDT
Celgene's (CELG) Otezla failed to meet the primary endpoint in a late stage study.
Lexicon (LXRX) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 8:46AM CDT
Lexicon (LXRX) was a big mover last session, with shares rising nearly 8% on the day.
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM
at The Street - Thu Jul 10, 5:00AM CDT
Cramer says Williams is a bargain, Unum is a slow and steady grower and Alcoa is reinventing itself.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
China Biologic Products, Inc. (CBPO) Jumps: Stock Surges 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:11AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:33AM CDT
Ultragenyx Pharmaceutical has seen flat earnings estimate revisions for the current quarter along with a significant rise in its share price for the past day
'Fast Money' Recap: Waiting for the Dust to Settle
at The Street - Wed Jul 09, 4:00AM CDT
The trading panel discussed the market's fall and how to hedge your positions.
Sanofi's Basal Insulin Candidate Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 5:40PM CDT
Sanofi's (SNY) new drug application for its basal insulin candidate, Toujeo, has been accepted for review by the FDA.
Biogen Idec Falls 2.48% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 2.48% Loss
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Jumps after Pain Drug Performs Well in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 3:45PM CDT
BioDelivery announced positive top-line results from a pivotal phase III efficacy study evaluating their pain candidate, BEMA buprenorphine.
Alexion Pharma Looks To Life Beyond Its Blockbuster
at Investor's Business Daily - Tue Jul 08, 1:42PM CDT
Like a rock band's second album, a biotech's second drug can say a lot about its long-term prospects. Alexion Pharmaceuticals (ALXN) is about to face this test. The 22-year-old firm has become a big-cap and a perennial on the IBD 50 list of top-rated...
Bristol-Myers Gains Japanese Approval for HCV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 10:40AM CDT
Bristol-Myers' (BMY) HCV combo drug has been cleared in Japan.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
BioDelivery Sciences International (BDSI) Rises: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 8:04AM CDT
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Oncolytics Biotech Inc. (ONCY) in Focus: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 7:44AM CDT
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.
